Ambeed.cn

首页 / 抑制剂/激动剂 / G蛋白偶联受体/G蛋白 / 血管紧张素受体 / Losartan potassium

氯沙坦钾 /Losartan potassium {[allProObj[0].p_purity_real_show]}

货号:A561984 同义名: DuP-753 potassium;Losartan (potassium salt)

Losartan potassium (DuP-753 potassium) 作为血管紧张素II受体1型(AT1)拮抗剂,竞争性抑制血管紧张素II与AT1的结合,IC50为20 nM。

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Losartan potassium 化学结构 CAS号:124750-99-8
Losartan potassium 化学结构
CAS号:124750-99-8
Losartan potassium 3D分子结构
CAS号:124750-99-8
Losartan potassium 化学结构 CAS号:124750-99-8
Losartan potassium 3D分子结构 CAS号:124750-99-8
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Losartan potassium 纯度/质量文件 产品仅供科研

货号:A561984 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell Host Microbe, 2024. Ambeed. [ A163338 ]
Cancer Res., 2024. Ambeed. [ A295334 ]
J. Pharm. Investig., 2024. Ambeed. [ A221527 , A691302 , A272538 , A187261 ]
J. Fungi, 2024, 10(11): 751. Ambeed. [ A796919 ]
JBC, 2024, 107935. Ambeed. [ A194396 ]
更多 >

Losartan potassium 生物活性

描述 The numerous effects of Angiotensin II (AII), including its roles in vasoconstriction, secretion of aldosterone and vasopressin, cellular proliferation, and hypertrophy are dominantly mediated through the activation of the angiotensin type 1 (AT1) receptor, a member of the superfamily of G protein-coupled receptors [5]. Losartan Potassium is an AII receptor antagonist that competitively binds the AT1 receptor with IC50 of 20 nM [6]. Male cynomolgus monkeys were given losartan (180 mg/d, n=6) or vehicle (n=8) for 6 weeks. Losartan caused significant (P<0.05) increases in plasma AII and angiotensin-(1-7). Compared with vehicle-treated controls, losartan reduced the extent of fatty streak in the aorta, the coronary arteries, and the carotid arteries by approximately 50% (P<0.05). A significant (P<0.05) reduction in the susceptibility of low-density lipoprotein (LDL) to in vitro oxidation, serum levels of monocyte chemoattractant protein-1, and circulating monocyte CD11b expression were also associated with losartan treatment [7].

Losartan potassium 动物研究

Dose Mice[3]: 0.1 mg/kg - 5 mg/kg (i.p.); 3 mg/kg, 30 mg/kg (p.o.) Rat[4]: 10 mg/kg (p.o.)
Administration i.p., p.o.
Pharmacokinetics
Animal Rats[4]
Dose 10 mg/kg
Administration p.o.
T1/2 3.27 ± 0.45 h
Tmax 0.73 ± 0.16 h
Cmax 1.33 ± 0.21 mg/L
AUC0→t 7.34 ± 0.75 mg·h/L

Losartan potassium 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT00763893 Marfan Syndrome Phase 3 Terminated(A similar publicati... 展开 >>on has been released, suggesting a beneficial effect of sartans, and only 15 patients remained to be seen for their visit at 36 months.) 收起 << - France ... 展开 >> Hôpital Bichat Paris, France, 75018 收起 <<
NCT01224860 Renal Transplant Phase 2 Completed - Italy ... 展开 >> Mario negri Institute - Clinical Research Center for Rare Diseases Ranica, Bergamo, Italy, 24020 收起 <<
NCT01620788 Hypertension Phase 3 Not yet recruiting March 2019 -

Losartan potassium 参考文献

[1]Habashi JP, Judge DP, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006 Apr 7;312(5770):117-21.

[2]Strawn WB, Chappell MC, et al. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000 Apr 4;101(13):1586-93.

[3]Vijayapandi P, Nagappa AN, et al. Biphasic effects of losartan potassium on immobility in mice. Yakugaku Zasshi. 2005 Aug;125(8):653-7.

[4]Zhao Q, Wei J, et al. Effects of quercetin on the pharmacokinetics of losartan and its metabolite EXP3174 in rats. Xenobiotica. 2019 May;49(5):563-568.

[5]Ojima M, Igata H, Tanaka M, Sakamoto H, Kuroita T, Kohara Y, Kubo K, Fuse H, Imura Y, Kusumoto K, Nagaya H. In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies. J Pharmacol Exp Ther. 2011 Mar;336(3):801-8. doi: 10.1124/jpet.110.176636. Epub 2010 Dec 1. PMID: 21123673.

[6]Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001 Feb 13;103(6):904-12. doi: 10.1161/01.cir.103.6.904. PMID: 11171802.

[7]Strawn WB, Chappell MC, Dean RH, Kivlighn S, Ferrario CM. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation. 2000 Apr 4;101(13):1586-93. doi: 10.1161/01.cir.101.13.1586. PMID: 10747353.

Losartan potassium 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.17mL

0.43mL

0.22mL

10.85mL

2.17mL

1.08mL

21.69mL

4.34mL

2.17mL

Losartan potassium 技术信息

CAS号124750-99-8
分子式C22H22ClKN6O
分子量 461.001
别名 DuP-753 potassium;Losartan (potassium salt);MK 954;DuP 753
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Room Temperature

溶解度

DMSO: 105 mg/mL(227.77 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

H2O: 50 mg/mL(108.46 mM),配合低频超声助溶

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。